Globus Medical, Inc. $GMED Stock Position Increased by Madison Avenue Partners LP

Madison Avenue Partners LP raised its stake in shares of Globus Medical, Inc. (NYSE:GMED) by 3.0% in the fourth quarter, Holdings Channel reports. The institutional investor owned 2,624,751 shares of the medical device company’s stock after buying an additional 76,588 shares during the quarter. Globus Medical accounts for about 9.8% of Madison Avenue Partners LP’s holdings, making the stock its 3rd biggest position. Madison Avenue Partners LP’s holdings in Globus Medical were worth $229,167,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. Advisory Services Network LLC bought a new position in Globus Medical in the 3rd quarter valued at approximately $26,000. EverSource Wealth Advisors LLC increased its holdings in Globus Medical by 74.3% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock worth $27,000 after buying an additional 197 shares in the last quarter. SBI Securities Co. Ltd. raised its position in Globus Medical by 98.2% in the 4th quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company’s stock worth $29,000 after buying an additional 167 shares during the last quarter. Parallel Advisors LLC lifted its stake in Globus Medical by 45.1% during the 3rd quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock valued at $32,000 after acquiring an additional 173 shares during the period. Finally, Headlands Technologies LLC lifted its position in Globus Medical by 485.4% during the second quarter. Headlands Technologies LLC now owns 761 shares of the medical device company’s stock valued at $45,000 after purchasing an additional 631 shares during the period. 95.16% of the stock is currently owned by institutional investors.

Globus Medical Trading Down 2.9%

GMED opened at $75.29 on Thursday. The firm’s 50 day simple moving average is $85.09 and its two-hundred day simple moving average is $87.80. The company has a market capitalization of $10.22 billion, a PE ratio of 17.51, a PEG ratio of 1.60 and a beta of 0.95. Globus Medical, Inc. has a 1-year low of $51.79 and a 1-year high of $101.40.

Globus Medical (NYSE:GMED) last issued its quarterly earnings data on Thursday, May 7th. The medical device company reported $1.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.92 by $0.20. The firm had revenue of $759.85 million during the quarter, compared to the consensus estimate of $740.35 million. Globus Medical had a net margin of 18.92% and a return on equity of 13.46%. The company’s revenue for the quarter was up 27.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.68 EPS. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. Equities analysts forecast that Globus Medical, Inc. will post 4.74 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the stock. Truist Financial set a $115.00 target price on shares of Globus Medical in a research report on Wednesday, February 25th. Wells Fargo & Company dropped their price target on Globus Medical from $104.00 to $103.00 and set an “overweight” rating on the stock in a research note on Friday, May 8th. Piper Sandler cut their price objective on Globus Medical from $115.00 to $100.00 and set an “overweight” rating for the company in a report on Monday. Needham & Company LLC increased their target price on Globus Medical from $114.00 to $117.00 and gave the company a “buy” rating in a report on Friday, May 8th. Finally, Royal Bank Of Canada raised their target price on Globus Medical from $115.00 to $120.00 and gave the stock an “outperform” rating in a research report on Friday, May 8th. Two analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $105.00.

Insider Activity

In related news, Director David D. Davidar sold 25,000 shares of the business’s stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $80.76, for a total transaction of $2,019,000.00. Following the completion of the transaction, the director directly owned 510,175 shares in the company, valued at approximately $41,201,733. The trade was a 4.67% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 18.38% of the company’s stock.

Globus Medical Company Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.